K-Ras基因突变型结直肠癌治疗的研究进展

发布时间：2018-10-13 13:18

【摘要】：结直肠癌是目前世界范围内致死率极高的一种恶性肿瘤,发病率呈逐年上升的趋势。当v-Ki-ras2 Kirsten大鼠肉瘤病毒癌基因同源物(v-Ki-ras2Kirsten rat sarcoma viral oncogene homolog,K-Ras)基因突变时患者极易出现复发和转移,严重影响了直结肠癌的治疗进程。耐药是肿瘤治疗中的主要问题,K-Ras基因突变型直结肠癌的耐药问题尤其突出,且目前缺少有效的治疗对策。随着对K-Ras基因突变后,肿瘤耐药、复发和转移机制研究的增多,直结肠癌分子标志物不断被发现,新型药物及相应的联合用药方案不断出现,K-Ras突变型直结肠癌的治疗也愈来愈趋向合理化,但其中仍存在许多问题。因此,本文将就K-Ras突变型结直肠癌的研究近况,从其突变特征、治疗难点、研究突破和未来预测等方面对K-Ras基因突变型直结肠癌的研究进展进行综述,希望能为后续临床治疗和研究提供一些有用参考。
[Abstract]:Colorectal cancer is a malignant tumor with high mortality in the world. The incidence of colorectal cancer is increasing year by year. When v-Ki-ras2 Kirsten rat sarcoma virus oncogene congener (v-Ki-ras2Kirsten rat sarcoma viral oncogene homolog,K-Ras) gene mutation, patients are prone to recurrence and metastasis, which seriously affects the treatment process of colon cancer. Drug resistance is a major problem in the treatment of cancer. The drug resistance of K-Ras gene mutant colorectal cancer is especially prominent, and there is a lack of effective treatment strategy. With the increase of studies on the mechanism of drug resistance, recurrence and metastasis of K-Ras gene, molecular markers of colorectal cancer have been found. With the emergence of new drugs and the corresponding combination of drugs, the treatment of K-Ras mutant colorectal cancer is becoming more and more rational, but there are still many problems. Therefore, this article will review the recent research progress of K-Ras mutant colorectal cancer, including its mutation characteristics, treatment difficulties, research breakthrough and future prediction. Hope to provide some useful reference for the follow-up clinical treatment and research.
【作者单位】：南京中医药大学药学院;江苏省中药药效与安全性评价重点实验室;江苏省中医药防治肿瘤协同创新中心;
【基金】：国家自然科学基金资助项目(编号:81673648,81673725,81573859) 江苏省自然科学基金资助项目(编号:BK2012854) 江苏省高校中药学优势学科建设工程资助项目[编号:苏政办发(2014)37号文] 中国博士后科学基金资助项目(编号:2014M551639)~~
【分类号】：R735.34

【参考文献】